L-Argininamide, N-(1-oxohexadecyl)-L-serylglycyl-L-arginyl-L-arginyl-L-tyrosylglycyl-L-histidyl-L-alanyl-L-leucyl-

PAR4antagonist which shows no agonist activity (as measured by platelet aggregation, intracellular Ca2+release or InsP production). Also inhibits Gαi-coupled formylpeptide FPR2 receptor downstream signaling but does not inhibit downstream signaling of the Gαq-coupled P2Y2 and PAF receptors. Additionally activates the FFAR2 short chain fatty acid receptor. Inhibits platelet aggregation and shows cardioprotective effects by decreasing infarct size before ischemia.

-20°C